Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 2
- 主要终点
- Safety and adverse events (AEs).
研究概览
简要总结
An observational study of patients with hematologic, oncologic, and other relevant conditions undergoing bone marrow imaging, with longitudinal collection of imaging, treatment, and clinical outcome data to characterize bone marrow features and changes over time
详细描述
Primary Objective
To establish a longitudinal cohort integrating bone marrow imaging with clinical and treatment-related data.
Primary Endpoint
Successful enrollment of eligible participants and collection of relevant imaging and clinical data.
Secondary Objective
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of a hematologic, oncologic, or other condition relevant to the study.
- •Availability of clinical, imaging, laboratory, treatment, and/or outcome data relevant to the study.
- •Ability to provide informed consent for prospective participation or, for pediatric participants, parent/legal guardian permission with assent when applicable.
- •Participants undergoing research MRI must be eligible for MRI according to institutional safety requirements.
排除标准
- •Inability to provide required informed consent or parental/legal guardian permission for prospective participation.
- •Insufficient clinical information to support study participation
- •Pregnancy.
- •Contraindication to MRI will exclude participants from research-specific MRI but not necessarily from other study components.
结局指标
主要结局
Safety and adverse events (AEs).
时间窗: Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Bone marrow imaging characteristics.
时间窗: Through study completion; an average of 1 year.
Evaluation of bone marrow imaging findings and longitudinal changes in patients with hematologic, oncologic, and other relevant conditions.
次要结局
未报告次要终点